Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology,and Management
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
IN BRIEF The threat and incidence of hypoglycemia is the major limiting factor in intensive glycemic control for both type 1 and type 2 diabetes. This article reviews the physiology of the normal counterregulatory responses to hypoglycemia and the deficient counterregulatory defenses that occur in patients with diabetes. Treatment paradigms for establishing good glycemic control while limiting hypoglycemia are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Self-citationEpidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Heller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Donnelly, L. A., Morris, A. D., Frier, B. M., Ellis, J. D., Donnan, P. T., Durrant, R., Band, M. M., Reekie, G., & Leese, G. P. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01501.x · Cited by 511
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Diverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411
Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.
Amiel, S. A., Sherwin, R. S., Simonson, D. C., & Tamborlane, W. V. (1988) · Diabetes · doi:10.2337/diab.37.7.901 · Cited by 393
Cited by
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Mechanisms of hypoglycemia unawareness and implications in diabetic patients
Martín-Timón, I. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.912 · Cited by 204
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
“Although careful titration of insulin therapy and intensive therapy with some sulfonylureas can achieve a good glycemic control without significant risk for hypoglycemia, a common limitation of intensive glucose lowering therapy is an increased risk for hypoglycemia.(5,6) Consequently, today type 2 diabetes is associa…”
Thorpe, C. T., Gellad, W. F., Good, C. B., Zhang, S., Zhao, X., Mor, M., & Fine, M. J. (2015) · Diabetes Care · doi:10.2337/dc14-0599 · Cited by 140
“Older individuals with dementia often have other risk factors for hypoglycemia, including weight loss, changes in appetite and eating habits, and difficulty following prescribed regimens (9–11), and a reduced ability to recognize and respond appropriately to symptoms (9,12,13).”
InfluentialHYPOS-1 Study Group of AMD, Giorda, C. B., Ozzello, A., Gentile, S., Aglialoro, A., Chiambretti, A., Baccetti, F., Gentile, F. M., Lucisano, G., Nicolucci, A., et al. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0713-4 · Cited by 97
Davis, S. N., Mann, S., Briscoe, V. J., Ertl, A. C., & Tate, D. B. (2009) · Diabetes · doi:10.2337/db08-1230 · Cited by 74
“, increased plasma glucose values) for counterregulatory defenses against hypoglycemia (7).”
Self-citationFeldman, S. M., Rosen, R., & DeStasio, J. (2009) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2009.02.010 · Cited by 70
“Nursing home patients are also prone to comorbidities such as UTIs.(20) Boyko et al(34) examined whether the presence of DM has an effect on the incidence of UTIs in postmenopausal women and confirmed that DM is associated with a higher risk of having an acute symptomatic UTI.”
BackgroundInfluentialImproved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts
Abraham, S. B., Arunachalam, S., Zhong, A., Agrawal, P., Cohen, O., & McMahon, C. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819859334 · Cited by 63
Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Peterson, G. E., & Pollom, R. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02498.x · Cited by 55
Mitchell, B. D., He, X., Sturdy, I. M., Cagle, A. P., & Settles, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15831.or · Cited by 46
Muneer, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_534 · Cited by 28
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22
Pilla, S. J., Kraschnewski, J. L., Lehman, E. B., Kong, L., Francis, E., Poger, J. M., Bryce, C. L., Maruthur, N. M., & Yeh, H.-C. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002153 · Cited by 16
Bajpai, S., Wong-Jacobson, S., Liu, D., Mitchell, B., Haynes, G., Syring, K., Ali, A. K., & Chinthammit, C. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.3.385 · Cited by 14
Cerebral Complications of Diabetes Mellitus
Aszalós, Z. (2007) · Orvosi Hetilap · doi:10.1556/oh.2007.28221 · Cited by 11
Metadata
- Authors
- Briscoe, V. J., & Davis, S. N.
- Venue
- Clinical Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-07-01
- Volume
- 24
- Issue
- 3
- Pages
- 115-121
- ISSN
- 0891-8929 (ISSN-L)
- 1945-4953
- OpenAlex
- W2126962035
- Cited by
- 174
- References
- 25
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.